N/A N=20 Can rTMS Enhance Somatosensory Recovery After Stroke?
Stroke
Primary: Change From Baseline in Two-point Discrimination — -0.7; -0.5; -0.1; -1.7 mm
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=109 Study of Enzastaurin Versus Placebo in the Treatment of Patients With Brain Metastases of Lung Cancer, After Whole Brain Radiation Therapy
Non Small Cell Lung Cancer · Small Cell Lung Cancer
Primary: Time to Progression of Brain Metastases — 6.9; 4.9 months
Phase 4 N=60 The ISLAND Study: InSuLa Assessed Needs for Depression
Depression
Primary: Number of Remission From Major Depressive Episode Events — 15; 4 number of events
Phase 2 N=29 HSCT For Patients With High Risk Hemoglobinopathies Using Reduced Intensity
Sickle Cell Disease · Beta Thalassemia-Major
Primary: Number of Participants With Sustained Cell Engraftment of Donor Cells — 29 Participants
N/A N=303 Continued Anticonvulsants After Resolution of Neonatal Seizures: a Patient-centered Comparative Effectiveness Study
Neonatal Seizures
Primary: WIDEA Neurodevelopmental Outcome Score — 149.04; 162.46; 148.80; 151.89 score on a scale
Phase 4 N=17 Imaging of 3D Innervation Zone Distribution in Spastic Muscles From High-density Surface EMG Recordings
Spasticity
Primary: Spasticity as Assessed by Reflex Torque of Elbow Flexors — 2.32; 2.04; 2.41; 3.11 Newton meter (n-m)
N/A N=60 Hyperglycemia in Renal Transplantation
Diabetes · End Stage Renal Disease
Primary: Incidence of Poor Graft Function After Kidney Transplant — 13; 22 Participants
Phase 4 N=95 An Extension Study to Provide Continued Bevacizumab Therapy to Participants With Solid Tumors Who Were Previously Enrolled in a Roche/Genentech Sponsored Study
Neoplasms
Primary: Percentage of Participants With Adverse Events — 90.9; 78.0; 71.4; 100.0 percentage of participants
Phase 2 N=64 Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple Myeloma
Recurrent Plasma Cell Myeloma · Refractory Plasma Cell Myeloma
Primary: Number of Participants With Dose Limitations Toxicities of the Combination of Lenalidomide and Thalidomide and Dexamethasone (LTD) in Patients With Relapsed/Refractory…
N/A N=66 The ConnectedCancerCare Pilot Study (CCC)
Early-stage Breast Cancer · Breast Cancer Female · Survivorship
Primary: Number of Breast Cancer Patients Successfully Recruited to Participate in the Study — 66 Participants
Phase 1 N=10 Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis Patients Infected With Burkholderia Cepacia Complex
Cystic Fibrosis · Burkholderia Cepacia Infection
Primary: The Change in Sputum Density of BCC in Colony Forming Units (CFUs)/ml From Day 0 to Day 28 of TIP Treatment. — -1.4 CFU/ml log10
N/A N=45 Assessment of the Efficacy of the Aerodentis System
Orthodontic Treatment · Tooth Crowding · Orthodontics
Primary: Litter's Index (Change in Little's Index Mean Total Score From Baseline) — 5.7; 6.2; 0.6; 0.3 mm
N/A N=2,227 Foley Bulb With Oral Misoprostol for Induction of Labor
Pregnancy · Labor, Induced
Primary: Number of Participants With Vaginal Delivery — 869; 860 Participants — p=0.86
N/A N=51 ATN 151 Work-to-Prevent: Employment as HIV Prevention
HIV Prevention
Primary: Information Systems Success Model Score — 4.4; 4.2 units on a scale
Phase 2 N=30 Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.
Covid19 · SARS-CoV-2 PNEUMONIA · COVID-19
Primary: Number of Participants With Non-serious and Serious Adverse Events During Trial — 0; 0; 0; 0 Participants